Analysis of the exposure of induced HIV glycoprotein epitopes in a potential HIV pseudovirion vaccine

Vaccine

Volumn 25, Issue 12, 2007, Pages 2161-2167

  Devitt, Gerard ^a   Emerson, Vanessa ^a   Pisch, Thorsten ^a   Keppler, Oliver T ^b   Bosch, Valerie ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

HIV pseudovirions; HIV vaccine; HIV Env induced epitopes

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 17B; MONOCLONAL ANTIBODY 48D; MONOCLONAL ANTIBODY CG10; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANTIGEN BINDING; ARTICLE; BINDING SITE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; MEMBRANE FUSION; MOLECULAR INTERACTION; MONOCLONAL ANTIBODY 8F101; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; VIRION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; EPITOPES; GLYCOPROTEINS; HIV; HIV ENVELOPE PROTEIN GP120; MICE; RECEPTORS, CXCR4; RECOMBINANT PROTEINS; VIRION;

EID: 33846874572     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.014     Document Type: Article

References (44)

1. Pantophlet R., and Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24 (2006) 739-769
2. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5 3 (2004) 233-236
3. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 5187 (1994) 1024-1027
4. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10 4 (1994) 359-369
5. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70 2 (1996) 1100-1108
6. Conley A.J., Kessler II J.A., Boots L.J., Tung J.S., Arnold B.A., Keller P.M., et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 91 8 (1994) 3348-3352
7. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67 11 (1993) 6642-6647
8. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75 22 (2001) 10892-10905
9. Fouts T., Godfrey K., Bobb K., Montefiori D., Hanson C.V., Kalyanaraman V.S., et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci USA 99 18 (2002) 11842-11847
10. Varadarajan R., Sharma D., Chakraborty K., Patel M., Citron M., Sinha P., et al. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J Virol 79 3 (2005) 1713-1723
11. Xiao X., Phogat S., Shu Y., Phogat A., Chow Y.H., Wei O.L., et al. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity. Vaccine 21 27-30 (2003) 4275-4284
12. Sparacio S., Pfeiffer T., Holtkotte D., and Bosch V. Inter-retroviral fusion mediated by human immunodeficiency virus or murine leukemia virus glycoproteins: independence of cellular membranes and membrane vesicles. Virology 294 2 (2002) 305-311
13. Sparacio S., Zeilfelder U., Pfeiffer T., Henzler T., and Bosch V. Membrane fusion between retroviral particles: host-range extension and vaccine prospects. Virology 271 2 (2000) 248-252
14. Zhou J., and Aiken C. Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope. J Virol 75 13 (2001) 5851-5859
15. Freed E.O., Myers D.J., and Risser R. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc Natl Acad Sci USA 87 12 (1990) 4650-4654
16. Freed E.O., Delwart E.L., Buchschacher Jr. G.L., and Panganiban A.T. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci USA 89 1 (1992) 70-74
17. Keppler O.T., Welte F.J., Ngo T.A., Chin P.S., Patton K.S., Tsou C.L., et al. Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med 195 6 (2002) 719-736
18. Lampe M, Briggs JAG, Endress T, Glass B, Riegelsberger S, Kräusslich HG, Lamb DC, Bräuchle C,Müller B. Double-labelled HIV-1 particles for study of virus-cell interaction. Virology, Nov 8 [Epub ahead of print].
19. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59 2 (1986) 284-291
20. Holtkotte D., Pfeiffer T., Pisch T., and Bosch V. Selection and characterization of a replication-competent human immunodeficiency virus type 1 variant encoding C-terminally truncated env. AIDS Res Hum Retroviruses 22 1 (2006) 57-65
21. Devitt G, Emerson V, Holtkotte D, Pfeiffer T, Pisch T, Bosch V. Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions. Virology 2006, doi:10.1016/j.virol. 2006.11.029, in press.
22. Henriksson P., and Bosch V. Inhibition of cellular glycoprotein incorporation into human immunodeficiency virus-like particles by coexpression of additional cellular interaction partner. Virology 251 1 (1998) 16-21
23. Kruger U., Pfeiffer T., and Bosch V. Generation of lymphocyte cell lines coexpressing CD4 and wild-type or mutant HIV type 1 glycoproteins: implications for HIV type 1 Env-induced cell lysis. AIDS Res Hum Retroviruses 12 9 (1996) 783-792
24. Signoret N., Oldridge J., Pelchen-Matthews A., Klasse P.J., Tran T., Brass L.F., et al. Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol 139 3 (1997) 651-664
25. Traunecker A., Oliveri F., and Karjalainen K. Myeloma based expression system for production of large mammalian proteins. Trends Biotechnol 9 4 (1991) 109-113
26. Chesebro B., Wehrly K., Nishio J., and Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 66 11 (1992) 6547-6554
27. Bosch V., and Pawlita M. Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site. J Virol 64 5 (1990) 2337-2344
28. Abacioglu Y.H., Fouts T.R., Laman J.D., Claassen E., Pincus S.H., Moore J.P., et al. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 10 4 (1994) 371-381
29. Gershoni J.M., Denisova G., Raviv D., Smorodinsky N.I., and Buyaner D. HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. Faseb J 7 12 (1993) 1185-1187
30. DeVico A.L., Rahman R., Welch J., Crowley R., Lusso P., Sarngadharan M.G., et al. Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120. Virology 211 2 (1995) 583-588
31. Sullivan N., Sun Y., Sattentau Q., Thali M., Wu D., Denisova G., et al. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol 72 6 (1998) 4694-4703
32. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67 7 (1993) 3978-3988
33. Cleveland S.M., McLain L., Cheung L., Jones T.D., Hollier M., and Dimmock N.J. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J Gen Virol 84 Pt 3 (2003) 591-602
34. McCallus D.E., Ugen K.E., Sato A.I., Williams W.V., and Weiner D.B. Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule. Viral Immunol 5 2 (1992) 163-172
35. Endres M.J., Jaffer S., Haggarty B., Turner J.D., Doranz B.J., O'Brien P.J., et al. Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes. Science 278 5342 (1997) 1462-1464
36. Schneider J., Kaaden O., Copeland T.D., Oroszlan S., and Hunsmann G. Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. J Gen Virol 67 Pt 11 (1986) 2533-2538
37. Moore J.P., McKeating J.A., Weiss R.A., and Sattentau Q.J. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250 4984 (1990) 1139-1142
38. Bugelski P.J., Ellens H., Hart T.K., and Kirsh R.L. Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: implications for clinical trials. J Acquir Immune Defic Syndr 4 9 (1991) 923-924
39. Chertova E., Bess J.W., Crise B.J., Sowder I.R., Schaden T.M., Hilburn J.M., et al. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 76 11 (2002) 5315-5325
40. Finnegan C.M., Berg W., Lewis G.K., and DeVico A.L. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J Virol 75 22 (2001) 11096-11105
41. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 6686 (1998) 648-659
42. Edwards T.G., Wyss S., Reeves J.D., Zolla-Pazner S., Hoxie J.A., Doms R.W., et al. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol 76 6 (2002) 2683-2691
43. Moore J.P., and Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 70 3 (1996) 1863-1872
44. Keppler O.T., Yonemoto W., Welte F.J., Patton K.S., Iacovides D., Atchison R.E., et al. Susceptibility of rat-derived cells to replication by human immunoficiency virus type 1. J Virol 75 17 (2001) 8063-8073